s MadCAM-1 as an immunological marker in the «gut liver axis» at patients with chronic hepatitis C and excess body weight

s MadCAM-1 as an immunological marker in the «gut liver axis» at patients with chronic hepatitis C and excess body weight

Background and aims: to estimate concentration of sMadCAM-1 in peripheral blood at patients with chronic hepatitis C with excess body weight.Materials and methods: The research included 88 patients (67 men, 21 women 41.4±3.2 years of age) with chronic hepatitis C (CHC) and excess body weight (the in...

Full description

Bibliographic Details
Main Authors:	K. V. Zhdanov, A. V. Semenov, S. S. Karyakin, K. V. Kozlov, V. S. Sukachev, Yu. V. Ostankova, D. E. Valutite, E. B. Zueva, R. S. Sidorov, A. V. Saulevich, Yu. I. Bulan’kov, Yu. I. Lyashenko, K. S. Ivanov
Format:	Article
Language:	Russian
Published:	Journal Infectology 2019-05-01
Series:	Журнал инфектологии
Subjects:	hepatitis c excess body weight small intestinal bacterial overgrowth liver fibrosis liver steatosis mucosal addressin cell adhesion molecule -1
Online Access:	https://journal.niidi.ru/jofin/article/view/885

Similar Items

Cholinergic Anti-inflammatory Pathway Attenuates Acute Liver Failure Through Inhibiting MAdCAM1/α4β7-mediated Gut-derived Proinflammatory Lymphocytes AccumulationSummary
by: Shan Fu, et al.
Published: (2024-01-01)

Bacterial overgrowth syndrome in patients with chronic diffuse liver diseases depending on the etiology and morphological features
by: V.I. Didenko, et al.
Published: (2019-09-01)

Circulating MAdCAM-1 and ITGB7 in Patients with Plaque Psoriasis and Eruptive Lichen Planus—Preliminary Data
by: Anna Baran, et al.
Published: (2021-11-01)

The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study
by: E. Scarpellini, et al.
Published: (2022-04-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale
by: K. V. Zhdanov, et al.
Published: (2021-01-01)

Elimination of hcv-infection: a history with continuation
by: K. V. Zhdanov, et al.
Published: (2018-12-01)

Value of abdominal ultrasound study in the evaluation of the liver parenchyma in potential related donors of liver fragments
by: Yu. R. Kamalov, et al.
Published: (2018-08-01)

Non-invasive diagnosis of fibrosis in patients with CHC and obesity
by: K. V. Zhdanov, et al.
Published: (2020-03-01)

Clinical and laboratory features of pancreatic steatosis in children with overweight and obesity
by: N.Yu. Zavgorodnyaya, et al.
Published: (2017-02-01)

Liver steatosis in brain death donors
by: D. V. Voronov, et al.
Published: (2021-04-01)

Chemokines and lymphocyte homing in Sjögren’s syndrome
by: Jiahe Liao, et al.
Published: (2024-04-01)

Association of the p.I148m polymorphism in the <i>PNPLA3</i> gene with the severity of nonalcoholic fatty liver disease in various clinical groups
by: D. V. Sidorenko, et al.
Published: (2024-04-01)

Amlodipine-induced gingival overgrowth in a child after liver transplant
by: André Guollo, et al.
Published: (2016-09-01)

Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Index for Classification of Patients with Steatotic Liver Disease
by: Akash Roy, et al.
Published: (2024-09-01)

Modern ultrasonic methods of diagnostics of hepatic steatosis
by: A. S. Kuznetsova, et al.
Published: (2023-08-01)

Small intestinal bacterial overgrowth in patients with chronic hepatitis C
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

The role of intestinal disbiosis in the development of mitochondrial dysfunction and nonalcoholic fatty liver disease
by: P. V. Seliverstov, et al.
Published: (2018-04-01)

Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics
by: A. V. Anisonyan, et al.
Published: (2020-09-01)

Ultrasound steatometry in patients with non-alcoholic fatty liver disease: pilot results
by: Darya Yu. Venidiktova, et al.
Published: (2019-04-01)

Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives
by: Georgiana-Diana Cazac, et al.
Published: (2023-04-01)

Subclinical markers of liver damage in patients with arterial hypertension and obesity
by: Irina A. Sadulaeva, et al.
Published: (2023-01-01)

Targeting Toll-like receptor 4 and microbiota dysregulation: a new frontier in nonalcoholic fatty liver disease management
by: K.B. Kvit
Published: (2024-12-01)

Fibrosis Predictive Score in Caucasian Patients with Metabolic Syndrome
by: Mare R, et al.
Published: (2022-06-01)

Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C
by: Maria Pokorska-Śpiewak, et al.
Published: (2017-05-01)

Hepatogenic weakness as a clinical marker of hyperammonemia and of the effectiveness of its correction in patients with pre-cirrhotic stages of non-alcoholic fatty liver disease
by: E. M. Petrova, et al.
Published: (2021-06-01)

Long Working Hours and Risk of Nonalcoholic Fatty Liver Disease: Korea National Health and Nutrition Examination Survey VII
by: Eyun Song, et al.
Published: (2021-05-01)

Long term N-acetylcysteine administration rescues liver steatosis via endoplasmic reticulum stress with unfolded protein response in mice
by: Ching-Chou Tsai, et al.
Published: (2020-05-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

Diagnostic markers of hepatic steatosis in patients with chronic viral hepatitis C
by: V. V. Tsvetkov, et al.
Published: (2023-05-01)

Evaluation of hepatic steatosis in obese children and adolescents using immune-inflammatory markers and shear wave elastography
by: Akçiçek Mehmet, et al.
Published: (2025-01-01)

Evaluation of Hepatic Steatosis in Rodents by Time-Domain Nuclear Magnetic Resonance
by: João A.B. Pedroso, et al.
Published: (2019-11-01)

Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients
by: Caroline Buss, R.D., Ph.D., et al.
Published: (2014-09-01)

Selective Targeting of α<sub>4</sub>β<sub>7</sub>/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver
by: Biki Gupta, et al.
Published: (2024-04-01)

Clinical and prognostic value of metabolic disorders in non-alcoholic fatty liver disease
by: Ya. M. Vakhrushev, et al.
Published: (2020-12-01)

Predictors of hepatic steatosis in living liver donors
by: M. G. Minina, et al.
Published: (2022-12-01)

LIPID METABOLISM DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C
by: L. I. Tkachenko, et al.
Published: (2015-12-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

Increased risk of vascular complications in patients with type 2 diabetes and fatty liver disease
by: Weixia Sun, et al.
Published: (2024-11-01)

Multifocal nodular lesions in fatty liver mimicking neoplastic disease: a case report
by: Manel Moalla, et al.
Published: (2023-04-01)